Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Capital Expenditures (2020 - 2025)

Bioventus (BVS) has disclosed Capital Expenditures for 6 consecutive years, with $580000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 248.72% year-over-year to $580000.0, compared with a TTM value of $2.6 million through Dec 2025, up 6000.0%, and an annual FY2025 reading of $2.6 million, up 6000.0% over the prior year.
  • Capital Expenditures was $580000.0 for Q4 2025 at Bioventus, up from $473000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.6 million in Q2 2023 and bottomed at -$5.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $304400.0, with a median of $526500.0 recorded in 2025.
  • The sharpest move saw Capital Expenditures crashed 5671.43% in 2024, then surged 5353.85% in 2025.
  • Year by year, Capital Expenditures stood at -$3.9 million in 2021, then crashed by 33.26% to -$5.2 million in 2022, then soared by 100.14% to $7000.0 in 2023, then plummeted by 5671.43% to -$390000.0 in 2024, then surged by 248.72% to $580000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BVS at $580000.0 in Q4 2025, $473000.0 in Q3 2025, and $683000.0 in Q2 2025.